FDA Expands VYVGART, VYVGART Hytrulo Label

The United States — Food and Drug Administration has approved a label expansion for Argenx's drugs, Efgartigimod alfa/hyaluronidase and Efgartigimod alfa/hyaluronidase, to include all adult patients living with generalized myasthenia gravis (gMG), regardless of serotype. This approval is based on data from the Phase 3 ADAPT SERON study, which demonstrated rapid, significant, and sustained symptom improvements in gMG patients. This expansion is a significant advancement for Argenx, as it broadens the potential patient population for its treatments and simplifies treatment decisions for clinicians. Key figures like Luc Truyen of Argenx and James F. Howard Jr. from the University of North Carolina at Chapel Hill highlighted the importance of this approval for patients who previously had limited treatment options.